据报道，Google DeepMind近期解散了负责AlphaFold研发的核心AI for Science团队[1]。AlphaFold论文的大部分原作者已被重新分配到其他项目[1]，其中部分研究人员转向Gemini相关研究，另有部分成员进入Isomorphic Labs[1]。这一变动发生在AlphaFold于2024年获得诺贝尔化学奖后[1]。
DeepMind在人员调整中进行了较大规模的重组。最初参与AlphaFold论文的DeepMind全职作者中已有近四分之一离开公司[1]。其中，AlphaFold核心负责人John Jumper曾被调往Code Strike团队，后来离开加入Anthropic[1]。DeepMind研究副总裁Pushmeet Kohli表示，这一战略"已经发生了演变"[1]。
Isomorphic Labs在2024年与诺华和礼来展开AI药物研发合作[1]。这一调整反映了DeepMind在当前AI竞争资源密集阶段，正从多条研究路线并行改为集中资源于通用大模型Gemini的发展[1]。
Google DeepMind has dismantled the core AI for Science team responsible for developing AlphaFold, according to reporting from July 29, following the project's recognition with the 2024 Nobel Prize in Chemistry [1]. The majority of original AlphaFold paper authors have been reassigned to other initiatives, with some transitioning to Gemini-related research and others joining Isomorphic Labs [1].
This reorganization signals a strategic pivot by DeepMind during an intensely competitive phase of AI development. The company has shifted from pursuing multiple parallel research tracks toward concentrating resources on the advancement of its general-purpose large language model, Gemini [1]. John Jumper, the core lead for AlphaFold, was previously reassigned to the Code Strike team before eventually departing to join Anthropic [1]. Pushmeet Kohli, DeepMind's vice president of research, characterized the change by stating that the company's strategy "has evolved" [1].
Nearly one quarter of the original full-time DeepMind authors who contributed to the AlphaFold paper have since left the company [1]. Meanwhile, Isomorphic Labs, where some former team members have been directed, has begun collaborating with Novartis and Eli Lilly on AI-driven drug development initiatives in 2024 [1].
